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ABSTRACT 
 
viDA Therapeutics Inc. (herein called viDA), with headquarters in Vancouver, British 
Columbia, was incorporated in April of 2008. viDA is a new specialty biotechnology company 
focused on the discovery, development and commercialization of first-in-class drugs for the 
treatment of age-related degenerative processes, such as age related wrinkling and hair loss. 
viDA has chosen a distinct company strategy, focusing strongly on the development and 
marketing of specialty products. viDA bases its business model in the remarkable and patented 
discoveries surrounding granzymes. Granzymes have been shown to play a central and pivotal 
role in the destruction of proteins vital in one’s body anti-aging processes that prevent skin 
wrinkling and hair loss. viDA is currently looking to secure an initial round of funding of $1.5 
million for 2008 and an additional $6 million for 2009 to perform further target identification, 
target validation, preclinical research and early-stage clinical development. We recommend that 
viDA seeks the full $7.5 million in Series A an Series B financing simultaneously to ensure 
adequate funds to meet projected milestones.  
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EXECUTIVE SUMMARY 
 
viDA Therapeutics is a new specialty biotechnology company focused on the discovery, 
development and commercialization of first-in-class drugs for the treatment of age-related 
degenerative processes, such as age related wrinkling and hair loss. viDA’s founders and Board 
of Directors include experienced industry biotech executives and pharmaceutical researchers 
with proven track records in discovery and translational research, R&D operations, product 
development, and business development. 
viDA has chosen a distinct company strategy, focusing strongly on the development and 
marketing of specialty products. viDA bases its business model in the remarkable and patented 
discoveries surrounding granzymes. Granzymes have been shown to play a central and pivotal 
role in the destruction of proteins vital in one’s body anti-aging processes that prevent skin 
wrinkling and hair loss. viDA first and foremost will ensure competency  and establish a strong 
presence in the field of medical aesthetics targeting local and international cosmeceutical 
markets by further developing proprietary inhibitors against the granzymes family. 
As already mentioned, much of viDA’s research efforts are centered on maximizing the 
value of the proprietary discovery in the biology of granzymes, targeting the cosmeceutical 
market. However, viDA will nurture a strategy for R&D that may form the basis for long-term 
growth and the potential to discover proprietary high-value therapies for a number of age related 
life threatening cardiovascular indications such as atherosclerosis, unstable angina and 
aneurysms.  
Granzyme B inhibitors are the company’s main growth driver. Granzyme B (GrB) is a 
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protease expressed by many immune cells that mediates programmed cell death.  viDA’s strong 
dependence on one key product may seem a concern, however, the company continues to invest 
significantly in the granzyme protein family, further expanding the therapeutic market presence 
of the product. viDA’s R&D has demonstrated that in conditions of chronic inflammation or 
aging elevated levels of granzymes accumulate and are capable of degrading structural proteins 
essential for maintaining tissue integrity, in particular, the elastic properties of blood vessels and 
skin.  
At present, viDA has few competitors in the local cosmeceutical market. However, 
Allergan/Elizabeth Arden through their strategic alliance, represent a strong competitor in both 
the US and the international cosmeceutical market. Allergan/Elizabeth Arden has developed a 
line of products (Prevage), which has been shown in human trials to be very effective in reducing 
age related skin conditions and with a major success in the cosmeceutical market after launch. 
viDA aims to launch a product line that will form the first significant threat to Allergan/Elizabeth 
Arden Prevage franchise. 
viDA is currently looking to secure its initial round of funding. viDA’s start-up time is 
estimated to occur over eight months and will require $3 million Canadian dollars. Upon 
commencing operations, viDA will require an additional $6,000,000 to ensure adequate cash 
flow over the following years of operations. The proceeds from this investment will support 
discovery and early stage development of proprietary granzyme inhibitors and a first line of 
products. viDA will look to advance and commercialize these products as a next generation of 
non invasive and highly effective cosmeceuticals. 
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Figure 1 - viDA’s Positioning Statement 
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GLOSSARY 
active site area in protease that is responsible for cleavage of 
other proteins 
apoptosis programmed cell death that involves a series of protein 
interactions and eventual death of a targeted cell 
arginine amino acid  
artery blood vessel that carries blood away from the heart 
aspartic acid amino acid 
atherogenesis the process that starts atherosclerosis or hardening of 
the arteries 
atherosclerosis hardening of the arteries caused by fat deposition that 
is accompanied by cell death and the growth of plaques 
chymostrypsin serine protease found in the intestine – digests proteins 
in food 
cleavage cutting by proteins in a specific area 
coronary related to the heart 
efficacy the power or capacity to produce a desired effect 
elastase serine protease found circulating in the body – cleaves 
elastin 
elastin ECM protein that gives elasticity to blood vessels, skin, 
etc 
enzyme inhibitors compounds or agents that combine with an enzyme in 
such a manner as to prevent the normal substrate-
enzyme combination and the catalytic reaction 
extracellular outside of the cell 
extracellular matrix (ECM) proteins  proteins that are outside of the cell that are structural.  
Examples would be elastin and collagen 
fibronectin ECM protein 
Granzyme B (GrB) protein that causes programmed cell death by cutting 
or cleaving other proteins 
hyperlipidemia high circulating fats and bad cholesterol in the blood 
kallikrein serine protease 
knockout genetically altered species where one or more genes are 
removed permanently 
lesions / plaques areas where atherosclerosis is present.  Can range from 
small fat streaks to well-developed, large, hard masses 
that block the space that blood can flow. 
medial thinning part of blood vessel where elastin fibers are present  
micromolar a concentration of one one-millionth of a mole per liter, 
typically used in reference to the concentration of a 
chemical compound in an aqueous solution 
pathology how a disease occurs; the study of disease 
peptidic inhibitors drugs/inhibitors made of proteins or peptides 
perforin a protein that is involved in allowing granzyme B to be 
released into target cells 
phenotypic characteristic that can describe a species that does not 
take into account the genetics.  An example of a 
phenotype is hair colour. 
protease proteins that cleave other proteins 
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serine protease protease that has a serine in its active site.  There are 
only a few proteases known to have this serine amino 
acid thus is an attractive target for drug inhibitors. 
substrate specificity How specific a protease can target its target.  This is 
dependent on structure, the sequence of the substrate, 
etc. 
thrombin serine protease involved in blood coagulation 
trypsin serine protease found in the intestine – digests proteins 
in food 
vascular blood vessel system in the body 
wild-type strains that do not have genes altered that are the 
strains that altered species start from 
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1 THE COMPANY AND THE CONCEPT  
viDA Therapeutics is an early-stage biotechnology company focused on the discovery 
and development of first-in-class drugs for the treatment of age-related degenerative processes, 
cardiovascular disease, and other inflammatory conditions. Based on new and remarkable 
discoveries surrounding aging and atherosclerosis-specific proteases, called granzymes, viDA is 
developing proprietary inhibitors against this family of protein-degrading enzymes that have 
been shown to play a central and pivotal role in the destruction of proteins vital for vascular and 
tissue integrity. 
viDA have demonstrated that in conditions of chronic inflammation or aging that 
elevated levels of granzymes accumulate and are capable of degrading structural proteins 
essential for maintaining tissue integrity, in particular, the elastic properties of blood vessels and 
skin. Moreover, when granzyme expression is blocked in animal models of disease, vessel-wall 
integrity is strikingly maintained and indicators of atherosclerosis and aneurysms are attenuated. 
In addition, there is marked reduction of hair loss and of skin degeneration. These notable 
discoveries offer the potential to discover proprietary high-value therapies for a number of life-
threatening cardiovascular indications such as atherosclerosis, unstable angina and aneurysms as 
well as lifestyle medicines for age-related wrinkling and hair loss. 
viDA was incorporated in April of 2008 and is located in Vancouver, British Columbia. 
viDA’s founders and Board of Directors include senior industry biotech executives and 
pharmaceutical researchers with proven track records in discovery and translational research, 
R&D operations, product development, and business development. In addition, viDA possesses a 
strong intellectual property position and unparalleled expertise in the biology of granzymes, 
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cardiovascular disease and age-related degenerative conditions. As a result, viDA has integrated 
the expertise and experience necessary to successfully create significant value through the 
development of a new class of therapies based on granzyme inhibitors. 
 
1.1  Long-term Growth Strategies  
viDA will target two large markets: the anti-aging market composed of “cosmeceuticals” 
(or lifestyle drugs) for the first stage (years one through 10) of viDA’s growth, and the multi-
billion dollar cardiovascular market which will be the second stage (years 10 and beyond) of 
viDA’s growth. Lifestyle drugs represent a diverse group of pharmaceuticals treating chronic, 
non-life-threatening conditions such as baldness, skin aging and sexual dysfunction, which are 
symptoms that are the by-products of natural aging. Success in developing novel clinical leads 
will result in composition of matter patents for a unique class of GrB inhibitors. This new 
Intellectual Property (IP) will allow viDA to enter the cardiovascular market, with blockbuster 
potential, owing to the prophylactic prescription of GrB inhibitors to prevent disease. viDA’s 
long-term strategy of entering the cardiovascular market will not be discussed in this plan. 
 
1.2 Product Description  
Research taking place in the laboratory of Dr. David Granville has recently resulted in 
several novel observations on the function of granzyme B. These discoveries will have a major 
impact in diseases and conditions associated with aging, including cardiovascular disease, 
baldness, and loss of skin elasticity leading to wrinkling. Granzyme B (GrB) is a protease 
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expressed by many immune cells that mediates programmed cell death. Until recently, the 
mechanism of action was thought to be immune cell delivery of GrB directly into cells targeted 
for destruction, where GrB cleaves key caspases that initiate an apoptotic cascade. Dr. Granville 
has demonstrated that in certain conditions GrB is also released by immune cells into the 
interstitial space surrounding cells and plasma. In this manner GrB can exert undesirable effects 
in a systemic manner leading to the destruction of key structural extra-cellular proteins that can 
lead to a loss of structural integrity of blood vessels and skin with increasing age. Another key 
observation from Dr. Granville’s laboratory is that GrB can cleave elastin. Taken together, a 
model emerges whereby GrB released by immune cells cleaves elastin associated with the blood 
vessels, hair follicles, and the skin, causing cardiovascular disease, baldness, and loss of skin 
elasticity, respectively.  At present, viDA’s strategy focuses on R&D surrounding GrB. The 
products identified will match the biotherapeutic characteristics viDA is searching for, based on 
the science of granzyme B. The marketing plan is based on the successful identification of a 
granzyme B inhibitor.  
Original studies from Dr. Granville’s laboratory found that GrB was elevated in humans 
with hyperlipidemia and advanced atherosclerosis. In these patients, the extent of GrB protein 
corresponded to the severity of atherosclerotic disease. To understand the mechanism, these 
observations were further explored and validated through Dr. Granville’s experiments using an 
ApoE knockout mouse which models hyperlipidemia and displays rapid onset cardiovascular 
disease, hair loss and skin problems. In those same mice, when GrB was disrupted, the mice 
displayed no cardiovascular disease, hair loss, or associated skin problems. The mice could best 
be described as robust, with a life span considered longer than normal.  
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In searching for potential lead compounds capable of inhibiting GrB, viDA was fortunate 
to learn of the work of Dr. Bob Sindelar. Dr. Sindelar’s research program has isolated several 
lead compounds capable of binding GrB. Further, he has selected the best candidate as an initial 
clinical lead, and elucidated the chemistry required to produce analogues in order to refine the 
binding kinetics and specificity. viDA is currently producing a select group of compounds that 
will potentially represent their first products. These results will shape the development strategy 
for viDA’s clinical lead refinement.  
 
1.3 Science in Detail  
Granzyme B — Dr. Granville’s laboratory is interested in understanding how different 
immunological and non-immunological factors contribute to vascular injury, dysfunction and 
atherogenesis. In particular, Dr. Granville has been interested in the GrB/perforin pathway, a 
major mechanism by which immune cells in the body get rid of unwanted cells such as tumour 
cells and virus-infected cells. GrB is a protease, or protein that cuts other proteins in a very 
specific manner, which is expressed predominantly by T-cells and NK cells. Upon stimulation of 
these cells by foreign antigen, GrB and perforin are released into the space adjacent to the target 
cell. Perforin inserts itself into the target cell’s membrane forming a pore, which in turn 
facilitates GrB entry into the target cell where GrB-mediated processes result in cell death.  
Although the majority of GrB is released uni-directionally towards the target cells, GrB 
can also be released non-specifically in the external space outside the cell. In vitro evidence 
indicates that non-target or bystander cells in the proximity of the target cell also undergo 
apoptosis (Choy, Hung et al., 2004).   With respect to the significance of non-specific GrB 
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release, Dr. Granville has shown that GrB is capable of cleaving certain extra-cellular matrix 
proteins in vitro such as fibronectin (as reviewed in (Buzza et al., 2005) and elastin (unpublished 
data). It is an intriguing prospect that low-level, non-specific GrB release may play a role in age-
related diseases associated with chronic inflammation through a mechanism consisting of matrix 
degradation and remodeling.  
 
Models for Granzyme B Function — Dr. Granville’s laboratory has recently 
demonstrated that the GrB/perforin pathway plays a critical role in the onset and progression of 
cardiac allograft vasculopathy, an accelerated form of atherosclerosis that is the leading cause of 
death in heart transplant recipients who survive more than one year (Choy et al., 2005; Choy, 
Kerjner, Wong, McManus, & Granville, 2004; Choy et al., 2003). Interestingly, in human 
coronary artery specimens isolated from patients who have moderate and severe allograft 
vasculopathy or atherosclerosis, GrB was found to localize to lipid-rich regions of the atheroma 
(vascular plaques). To further study the role of GrB in atherogenesis and its relationship to 
hyperlipidemia, ApoE and GrB double-knockout mice were generated. In an experiment, four 
groups of mice consisting of (1) control wild-type, (2) ApoE-knockout, (3) GrB-knockout, and 
(4) GrB/ApoE-double knockout were fed a normal chow or high fat ‘Western’ diet (21% fat, 
0.2% cholesterol) for 30 weeks. No obvious phenotypic differences were observed in these mice 
during the first three months, however by 30 weeks when the mice were sacrificed and tissues 
were harvested, the ApoE-knockout mice had aged more rapidly, developed severe skin lesions, 
hair loss, and numerous atherosclerotic lesions similar to that previously described in the 
literature (see Figures 2 and 3).  
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From: Cruz RP, Boivin WA, Chamberlain CM, Zhao H, Choy JC, McManus BM, Granville DJ.  Granzyme B is important in the progression of 
atherosclerosis. Experimental Biology - FASEB 2008, San Diego, California, USA 
 
The absence of the GrB gene in the GrB/ApoE double-knockout mice significantly 
reduced both the frequency and size of atherosclerotic lesions (Figure 3). Equally striking were 
the significant reduction of skin lesions and the presence of a full coat of fur in the GrB/ApoE-
double knockout (Figure 3; bottom right) compared to the ApoE-knockout (Figure 3; bottom 
left). Excitingly, although the ApoE-knockout mice on a Western diet must be sacrificed around 
six to seven months for humane reasons, the ApoE/GrB double-knockout mice have aged to over 
12 months of age with no visible signs of aging or illness. The latter observation, in combination 
with the reduced incidence of atherosclerosis, indicates that GrB plays a major role in 
pathologies associated with ApoE deficiency, aging and hyperlipidemia.  
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Granzyme B as a Target for Drug Development — GrB is an especially attractive 
target for drug design because of its substrate specificity. There are numerous serine proteases 
other than GrB including: trypsin, chymotrypsin, elastase, kallikrein, and thrombin. These other 
serine proteases are involved in various physiological functions like: blood coagulation, clot 
dissolution, digestion, protein metabolism, immunological response, fertilization, and 
developmental regulation. A compound that inhibits the action of GrB and does not discriminate 
amongst other serine proteases could cause any number of detrimental side-effects. However, 
GrB possesses unique substrate specificity due to an arginine residue positioned in the active site 
of the enzyme. This buried arginine can interact with acidic peptides, which results in GrB’s 
preference for substrates with an aspartic acid at the site of cleavage. In addition to its acidic 
substrate specificity at the P1 position (binding site notation), GrB also prefers Ile or Val at P4, 
Glu, Met, or Gln at P3, an uncharged residue at P1’, and Gly or Ala at P2’. With such a unique 
substrate specificity profile among the proteases, development of a specific inhibitor of GrB 
becomes very feasible.  
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From: Cruz RP, Boivin WA, Chamberlain CM, Zhao H, Choy JC, McManus BM, Granville DJ.  Granzyme B is important in the progression of 
atherosclerosis. Experimental Biology - FASEB 2008, San Diego, California, USA 
 
The scientific literature is currently void of any communications describing non-peptide 
inhibitors of GrB. Peptidic inhibitors of GrB have been developed, but these are primarily tools 
for exploring enzyme structure and function. Peptides, as drug candidates are inferior to their 
non-peptide counterparts, in that they have numerous pharmacological problems associated with 
them in regards to their absorption, distribution, metabolism, and excretion profiles (ADME) in 
vivo. Thus, the development of potent and selective non-peptide inhibitors of GrB with an 
acceptable ADME profile is very desirable.  
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2 MANAGEMENT TEAM  
2.1 Key Management Personnel and Responsibilities  
Alistair Duncan, C.A. – Founder and President and CEO of viDA Therapeutics. Mr. 
Duncan was previously President and CEO of Chromos Molecular Systems Inc., where he was 
also a founder and Director. Prior to that, he was a Principal with the Ernst & Young Corporate 
Finance and International Life Sciences Group where he provided high technology and life 
sciences companies with corporate advisory services in strategic planning, valuations, financing, 
divestitures, and mergers & acquisitions. Currently, Mr. Duncan also serves as a director on the 
boards of the Michael Smith Foundation for Health Research, Agrisoma Biosciences Inc. and 
Migenix Inc (TSX: MGX). Mr. Duncan holds a C.A. designation and a B.Sc. in Biochemistry 
from the University of British Columbia. 
 
Harry C. Ledebur, Jr., Ph.D. – Founder, Dr. Ledebur currently serves as Vice President 
Research & Development, Chief Scientific Officer for US based private company, NanoMed 
Pharmaceuticals Inc., Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations 
and Scientific Affairs at Chromos Molecular Systems. Previously, he was with Caprion 
Pharmaceuticals Inc. where he served as Vice President of Discovery Programs and Vice 
President of Research & Development. Dr. Ledebur also served as Program Head of the Antigen 
Presenting Cell Program at Valentis, Inc. (formerly GeneMedicine, Inc.) where he focused on the 
development of DNA-based vaccines for cancer and infectious disease. He began his career at 
Boehringer Ingelheim Pharmaceuticals Inc. as a Research Fellow. Dr. Ledebur received his 
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Ph.D. in Molecular & Cell Biology from Pennsylvania State University and his B.Sc. in 
Biochemistry from The Ohio State University. 
 
David Granville, Ph.D. – Scientific Founder, Dr. Granville, is an Associate 
Professor/Canada Research Chair at the Providence Heart and Lung Institute at St. Paul’s 
Hospital, UBC. A Tier II Canada Research Chair, Dr. Granville is also a Michael Smith 
Foundation for Health Research Scholar and in 2004 was awarded a Canada Top 40 Under 40™ 
award by Caldwell and Partners. He also received the 2006 UBC Outstanding Young Alumnus 
Award, the 2007 SFU Academic Alumnus Award and was a finalist for the 2007 Louis and 
Arnold Katz Basic Science Prize at the American Heart Association Scientific Sessions. Dr. 
Granville received his Ph.D. in Experimental Pathology from the University of British Columbia 
and his B.Sc. from Simon Fraser University. 
 
2.2 Supporting Professional Advisors and Services  
Current Members of the Board of Scientific and Medical Advisors:  
Julia Levy, Ph.D. – Chair of the Board and Founder of QLT, Dr. Levy served in several 
key senior posts at QLT including Chief Scientific Officer and Vice President as well as 
President and CEO from 1995 to February 2002. Dr. Levy was also a Director of QLT since 
1983 and in December 2006, retired from the Board to become Director Emerita. She was 
actively involved in QLT’s Scientific Advisory Board until January 2008 when she retired from 
QLT entirely. Following her doctorate degree in immunology from the University of London, 
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Dr. Levy was awarded an Industrial Professorship in the Department of Microbiology from the 
University of British Columbia and is the recipient of several honorary degrees. A fellow of the 
Royal Society of Canada and former President of the Canadian Federation of Biological 
Sciences, Dr. Levy has earned numerous awards and honors, including an appointment as an 
Officer of the Order of Canada in 2001, the Female Entrepreneur of the Year for International 
Business in 1998, Pacific Canada Entrepreneur of the Year in 2000 and the Future of Vision 
Award from the Foundation Fighting Blindness in 2001. In 2002 she received, along with Dr. 
David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada 
research award. Along with Dr. Gustav Huber of Novartis, she was presented with the 2003 
Helen Keller Prize for Innovation in Eye Care. In her honor, the Julia G. Levy Professorship in 
Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the 
same year she was awarded the Lifetime Achievement Award from the British Columbia 
Biotechnology Association. The author of many published scientific articles and a sought-after 
speaker, Dr. Levy currently serves as a director on a number of early-stage biotechnology 
company boards and on the board of the Working Opportunity Fund, a British Columbian, 
Canadian-based venture capital firm. 
 
Darrell Elliott – Member of the Board, Mr. Elliott has more than 35 years of experience 
in merchant banking, venture capital and analogous operating experiences in Africa, Europe and 
North America. He has served on numerous boards and sub-boards of both private and publicly 
traded companies. Mr. Elliott is Chairman, CEO and one of the original founders of Apex 
Bioventures Acquisition Corp., a publicly traded company listed on the American Stock 
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Exchange (“AMEX”). Mr. Elliott is the Chairman and interim CEO of Virexx Medical Corp, a 
publicly traded company on the TSX and AMEX, and also a director of publicly-traded 
companies, SMC Ventures Inc., Auricle Biomedical Corporation and Transformative Ventures 
Ltd., as well as Discovery Parks Trust and several private companies. Earlier, Mr. Elliott was 
Senior Vice President and Managing Director of MDS Capital Corp., President of MDS 
Ventures Pacific, Chairman and Chief Executive Officer of British Columbia Medical 
Innovations Fund, Vice President of Canadian Medical Discoveries Fund and Regional Vice 
President and Managing Director of Royal Bank Capital Corporation. 
 
Alistair Duncan, C.A. – Member of the Board (see above for biography) 
David Granville, Ph.D. – Member of the Board (see above for biography) 
 
3 MARKET ANALYSIS AND RESEARCH  
3.1 Market trends  
During the first stage of company development, viDA will target the large anti-aging 
market. The anti-aging market is young and predicted to grow and expand. With revenues of $56 
billion a year in 2006, the anti-aging market is targeted to reach $79 billion by 2009 (Weintraub, 
2006). Within the biotechnology industry, companies focused on cosmetics and toiletries 
reported the highest growth rates in five years, increasing 10% to over $253 billion in global 
sales in 2006 (Nasto, 2007). Furthermore, significant growth has been seen in market indicators, 
such as Botox, which reported a 12% growth from 2003 to 2007, and Restalyne and semi-
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permanent fillers, where 190% growth between the years 2003 to 2007. The success of viDA in 
the anti-aging market will be linked to the increasingly high demand by clients for anti-aging 
products, as increased life expectancy and reduced mortality stimulate consumer demand for 
lifestyle drugs.  
 
3.2 Industry Analysis  
The worldwide annual expenditures for cosmetics is estimated at $18 billion USD 
(Mayell, 2004). Of the major firms, the oldest and the largest is L’Oréal, which was founded 
by Eugene Schueller in 1909 as the French Harmless Hair Colouring Company (now owned 
by Liliane Bettencourt 26% and Nestlé 28%, with the remaining 46% publicly traded). The 
market was developed in the USA during the 1910s by Elizabeth Arden, Helena Rubinstein, 
and Max Factor. Revlon joined the market just before World War II and Estée Lauder, not long 
after the war. Like most industries, cosmetic companies have continued to resist regulation 
by government agencies like the FDA, and have lobbied against this throughout the years 
(Lewis, 1998).  
viDA’s initial market-sector target, the anti-aging market, encompasses a large variety of 
“Cosmeceuticals”, which represent a diverse group of pharmaceuticals targeted towards chronic 
non-life-threatening conditions such as baldness, skin aging and sexual dysfunction, all 
symptoms that are the by-products of natural aging. The steady increase in the baby boomer 
demographic is expected to drive the growth of the lifestyle drug sector over the next 30 years. 
Today, one person in ten is estimated to be over the age of 60, which is expected to increase to 
one in five by 2050 with an associated increase of in the number of elderly individuals by 300% 
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(Bureau, 2008b).  Increased life expectancy and reduced mortality will create a demand for 
lifestyle drugs as evidenced by Viagra and Botox, and will be realized through our development 
of GrB inhibitors.  
viDA will potentially target two primary lifestyle issues: 
1. Baldness - One of the largest lifestyle sectors relates to baldness as discussed 
previously. This market includes 35% of men at 35 years of age and 75% of men at age 80 
(Bureau, 2008b). In the USA alone, there are 45 million men who have experienced thinning or 
receding hair (National Institutes of Health, 2008). As a result, there is a large market for 
treatments for baldness. Currently, the sector is occupied by the following products:  
 
Table 1 – Companies and products within the balding market. 
Drug  Compan(ies) Description  
Azelaic 
acid/Skinoren  
Various (eg. Schering Pty Ltd; Ego 
Pharmaceuticals Pty Ltd) 
Commonly used in the treatment of 
acne, inhibits 5-alpha reductase  
Corticosteriods  Various (eg. Eurand) Cream or lotion applied to scalp  
Propecia  Merck Oral drug approved for use in men  
PUVA/psoralen  Various (eg. Dayang Chemicals 
Co. Ltd.; Chemos GmbH) 
Light sensitive drug activated by UV 
light  
Retin-A 
(tretinoin)  
Various (eg. Ortho-Neutragena) Topical gel applied to scalp  
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Rogaine/Regaine 
(minoxidil)  
Merck Topical cream applied to scalp  
Saw Palmetto 
Extract  
Saw Palmetto Harvesting 
Company 
Anti-androgen agent effective for 
benign prostatic disease also show 
promise in balding  
Zinc  Various (eg. Chemisfair; Zycon) Oral high doses of zinc produce 
immunomodulatory and anti-
andronergic effects, but cause side 
effects such as vomiting and diarrhea  
  
The most efficacious of these products also have the most unwanted side effects. As 
creams, the medication tends to spread, which can promote the growth of hair in unwanted 
places. These medications can, at best, slow the loss of hair, but not halt or reverse it. As a result, 
the percentage of men who seek treatment is but a fraction of the potential patient population. 
The market size was $340 million in 2001 and dominated by Propecia and Rogaine.  
  
2. Skin Aging/Skin Damage - An obvious choice for lifestyle drug development relates 
to the treatment of skin aging. The market is already booming and anti-aging products comprised 
the fastest-growing sector of the $10 billion worldwide cosmeceutical market since 1997. 
Current estimates of anti-aging therapeutics administered worldwide are in the region of $970 
million according to the American Academy of Anti-Aging Medicine. Many cosmeceutical 
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companies have cashed in on the high consumer demand and have been selling inefficacious 
products. Anti-aging pharmaceuticals for skin would thus have the advantage that consumers 
would be reassured by scientific validation of pharmaceutical products. The pathophysiology of 
skin aging is marked by wrinkles, reduction in thickness, inelasticity and coarseness, all of which 
are associated with loss of elastin in the skin. Thus a topical GrB inhibitor has promise for 
blockbuster potential within this market. In the US, more than 33 million people seek treatment 
from dermatologists for skin complaints. The number of people seeking skin anti-aging 
treatments in the future is expected to increase substantially as media focus on anti-aging 
treatments expands and intensifies. More women than men are expected to drive this trend owing 
to society’s preoccupation with youth and beauty.  
Current products in this space include: Retin-A (tretinoin), which is commonly used to 
treat acne and has off label use for skin aging; Renova/Retinova (tretinoin) indicated for 
wrinkles; and Botox (botulinium toxin type A) a bacterial toxin that de-enervates muscles and 
smoothes the skin.  
  
3.3 Limitations of the Market 
Because lifestyle drugs are perceived as treatments for non-life-threatening medical 
conditions, healthcare payers and governments may refuse to reimburse patients for their 
purchase. This has created a particular problem in the USA where insurance providers 
simultaneously seek to satisfy customer demands while maintaining costs. Recent court cases 
have favoured insurers who have refused to reimburse patients for the purchase of Viagra. 
Currently the reimbursement policy across private insurers and public sector government 
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healthcare plans is fragmented.  Many of these products have an active ingredient, which is 
deemed to be regulated by the FDA/Health Canada, thus will affect pricing as these products 
must undergo expensive clinical trials. 
The reputation of the “pseudo-science” cosmeceuticals and fear of liability should 
the treatment go wrong, however, are dissuading big pharmaceutical drug companies from 
entering the field. However, some experts predict that the firms’ attitudes could change as their 
parched product pipelines make them increasingly desperate for commercial success. Most 
cosmetics firms, meanwhile, have little incentive to enter the regulatory morass of the drug 
business, given that they can make healthy profits from their existing range of creams and 
lotions. According to the FDA’s definition, drugs are agents used in the diagnosis, 
cure, mitigation, treatment or prevention of disease, or which are intended to affect the structure 
or function of the body. Cosmetics, on the other hand, do not require extensive testing and FDA 
approval before they hit the market, because they simply alter personal appearance.  
Cosmeceuticals can be viewed as drugs that affect personal appearance, or cosmetics 
that change the structure or function of human bodies. For the big pharmaceuticals their interests 
have not yet shifted towards cosmeceuticals as they are likely to make only a fraction of the 
profits that can be earned by conventional blockbuster drugs. In addition, 
the potential of liabilities is also enormous. Patients are usually willing to accept a risk of 
experiencing a side effect in treating their disease. But someone that takes a drug for its cosmetic 
effects is likely to hold companies to a greater degree of liability for side effects (Pearson, 2003). 
Together, viDA’s industry threats are shown in the figure below. 
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Figure 4 - viDA’s Industry Threats 
 
As Figure 4 shows, the threat from entrants is limited due to several factors.  The patents 
and intellectual property that viDA holds will prevent others from entering in the same field of 
research.  Furthermore, there are incredible amounts of tacit knowledge which enables viDA to 
benefit from economies of learning.  Therefore, the ability of competitors to enter this market is 
challenging.  The ability for new entrants to attract financing based on generic formulations will 
be limited because of viDA’s first in market status.  
However, competition that viDA is facing is well-established with a series of products 
already in the market which may be viDA’s greatest threat.   Furthermore, they are vertically-
integrated, have large budgets, established awareness and visibility with target segments, and 
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dedicated sales forces and distribution chains. 
viDA views the threat of substitutes as very minor.  This is because surgery is extremely 
invasive and expensive, and for many of the target segments, is not an option.  Furthermore, 
homeopathy and health styles are more of a complement rather than a complete substitute.  
Lastly, acupuncture is less efficacious yet still invasive. 
The threat from suppliers is low as a large number of companies that produce products in 
the supply chain is large.  In fact, contract research organizations operate in a highly competitive 
industry where supplies are priced competitively.    
There is no threat of customers since the consumer base of anti-aging products is large 
and growing.  The same is through of complements. 
 
3.4 Competition  
3.4.1 viDA’s Competitors  
The anti-aging market is serviced by hundreds of companies that have market shares that 
range from 6% (Rogaine) to 89% (Botox). The following table lists the competing products, key 
strengths and weaknesses, product prices, distribution channels, intellectual property and 
strategic alliances of viDA’s key competitors.  
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Table 2 – viDA’s key competitors 
Company Allergan Inc. Allergan Inc. Medicis Johnson 
&Johnson  
Product: Prevage  Botox  Restylane  Renova 
Key 
Strength:  
- easy to apply, no 
prescription, crème  
- major reduction and 
removal of fine lines 
and lesser facial 
wrinkles, smoothing 
over and filling of 
deeper, more prominent 
facial expression lines 
& wrinkles 
- well studied and FDA 
approved 
- simple, non-surgical 
procedure 
- relaxes the dominant 
facial muscles 
- can last up to four months  
- common and 
easy to perform 
procedure takes 
less than 30 min 
with minimal 
discomfort and 
pain 
- results are almost 
immediate 
- first prescription 
approved by the FDA for 
treatment for wrinkles and 
proven to reduce fine 
facial wrinkles 
Key 
Weakness: 
- slight skin irritation 
upon initial days of 
application 
- expensive  
- temporary 
- serious heart problems 
and serious allergic 
reactions 
- side effects following 
injection include temporary 
eyelid droop and nausea, 
localized pain, infection, 
inflammation, tenderness, 
swelling, redness, and/or 
bleeding/bruising 
- patients with certain 
neuromuscular disorders 
may be at increased risk of 
serious side effects 
- does not contain 
anesthetic, so 
discomfort is 
greater than other 
injected treatments 
- allergic reactions 
common 
- requires repeat 
treatments every 6 
months. 
- no longer being 
manufactured for sale in 
Canada 
- patients may experience 
some redness, itching, 
dryness or peeling 
- is a dermal irritant 
- does not eliminate 
wrinkles, repair sun-
damaged skin, reverse 
photoaging or restore more 
youthful or younger skin 
Price:  - face $349, 1.5oz, 
- eye $183, 0.5 oz 
- $400 for doctors 
- between $500 and $2000 
for patients, depending on 
the areas treated 
- lasts 4 - 6 months  
- $300 - $1,000 
(typically $700 per 
cc) 
- follow-ups 
required every 6 
months 
- $150/40 grams 
Distribution:  - over-the-counter 
- cosmetic shops 
- spas 
- online  
- administered by trained 
and qualified physicians 
- available only by 
prescription 
- available only 
through a licensed 
health care 
professional 
- available only through a 
licensed health care 
professional 
Strategic 
alliances: 
- Elizabeth Arden  - Clinique Laboratories, 
LLC 
- new skin care line, will be 
sold exclusively in US 
physicians' offices in fall 
2008 
- many medical 
professionals using 
co-treatments of 
Restylane and 
Botox 
- marketed by 
OrthoNeutrogena, 
marketing 
- branding by Stratagem 
Healthcare 
Communications 
Patents:  - three patented 
peptides 
- formula expires 2026 
- patent expired in 2006 - patent expires in 
2009 
- patent expired in 2006 
Additional 
information: 
- Prevage MD, by 
prescription only, 
utilizing the main 
ingredient, Idebenone  
- three major treatment 
categories offered  
1) cosmetic,  
2) therapeutic for select 
neurological diseases  
3) severe underarm 
sweating  
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Company Merck  McNeil DermaPlus DermaGenetics 
Product: Propecia Rogaine Dermalastyl-β Dermagenetics  
Key 
Strength:  
- first clinically proven 
treatemnt for hair loss 
- first oral treatment 
taken once a day for the 
prevention of further 
hair loss and for re-
growth in the most 
common sites of hair 
thinning in men 
- does not lose patent 
protection till 2013 
- male and female-specific 
products; contains 
Minoxidil, the only 
ingredient that is FDA 
approved and proven to 
regrow hair in women 
- clinically proven to 
regrow hair 
- is available in an easy-to-
use foam 
- nongreasy, doesn’t drip, 
and dries quickly 
- water soluble and 
intact protein that 
has higher skin 
absorbency 
- lesser chance of 
reaction 
- more esthetically 
acceptable than 
competing 
cosmeceuticals  
- proprietary 
technology to 
design and 
manufacture 
personalized 
biomaterials that 
have obvious 
performance and 
marketing 
advantages over 
existing materials 
- reduces wrinkles 
by 45% in 2 
months 
- uses single nucleotide 
polymorphisms (SNPs) 
from each individual to 
prepare a customized 
treatment 
- DNA skin analysis offers 
customized treatment 
based on skin genes 
- personal DNA 
UltraCustom formula 
Key 
Weakness: 
- masks levels of 
prostate cancer antigen, 
which might lead to 
false negatives 
- decreases libido and 
causes erectile 
dysfunction 
- for use by men only 
- reproductive risks for 
women for  
- may be harmful if used 
when pregnant or breast 
feeding 
- not sanctioned by 
the medical field 
- not sanctioned by the 
medical field 
Price:  - $59-69 for a 1 month 
supply 
- 1 year therapy 
recommended 
- $29.95 for a one month 
supply 
- $89 USD for 2 
month supply 
- $89 USD for 2-month 
supply 
Distribution:  - available only through 
prescription online 
DTCA 
- available without a 
prescription 
- online DTCA and sales 
- online sales only - online sales and spa 
professional 
- retailed exclusively 
through qualified spas, 
skin care businesses and 
professional offices that 
are under the direction of 
(licensed) health-care 
professionals, aestheticians 
or physicians. 
Strategic 
alliances: 
- none - none - none - none 
Patent 
Expiry: 
- patent expires 2013 - patent expired 2000 - patent expires 
2019 
- patent expires 2009 
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3.5 Market Segmentation and Targeting  
3.5.1 Segmentation  
viDA has identified at least four main market segments for Lifestyle Stage 1 targets:  
1) medical professionals 
2) people at risk for hair loss 
3) baby boomers, and  
4) beauty-conscious individuals.  
The first and most effective market segment viDA will target is medical professionals. The 
ability of medical professionals to influence patients and consumers sets this segment apart from 
the others, and buy-in from medical professionals will be essential to successful product 
diffusion.  
In North America, medical professionals involved in the anti-aging industry include 
dermatologists, cosmetic surgeons and medical professionals certified by the American Academy 
of Anti-Aging Medicine. Together, this group represents approximately 31,000 professionals in 
Canada and the USA that viDA will target during the company’s initial marketing campaigns 
(Appendix II).  
It is perhaps unsurprising that over $76 million CAD is spent on hair transplants, as 40% 
to 50% of men and women by the age of 50 experience hair loss (National Institutes of Health, 
2008). In fact, word-wide spending on hair restoration was estimated at one billion dollars in 
2006. Accordingly, people at risk for hair loss are a secondary market for viDA Therapeutics, 
with approximated 101 Million North Americans affected. Similarly, baby boomers will be 
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targeted as consumers of viDA products, increasing viDA’s target markets to include 72 million 
baby boomers. Another segment encompasses the 3.8 million beauty-conscious individuals, 
defined as females between the ages of 30 and 49, who are typical “health seekers”, that are 
employed full-time with an average income of $36,000 per year (see Appendix II).  
 
3.5.2 Market Size  
Together, medical professionals, people at risk for hair loss, baby boomers and beauty-
conscious individuals make up a potential market of over 177 million consumers. The market-
size calculations and primary sources of this information can be found in Appendix II.  
 
3.5.3 Target Segment  
The importance of medical professionals as the first target market for viDA is evidenced 
by the trust that the general public on the whole places in medical professionals. Indeed, doctors 
are legally regarded as “learned intermediaries” who are liable for the ramifications of their 
advice and opinions regarding risks and benefits of medical and health products. Patients will 
trust their doctor’s professional expertise and good judgment to be the final word on the products 
that they recommend (Brown, 2005).  
The business of improving personal appearance by medical means is vast and is growing 
in many directions. Along with cosmeceuticals, a wide range of treatments are available in 
doctors’ offices. Chemical peels, laser treatments, micro-dermabrasion, which were once 
primarily the purview of spas and beauty clinics, are now common offerings at many 
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dermatologists’ and cosmetic surgeons’ offices. 
Doctors are opening their own spas, lending their names to various product lines, and 
writing books detailing methods that allegedly keep skin youthful. About half of all 
dermatologists sell cosmetic products in their offices, as they see that distributing these retail 
products adds essentially to their profits and therefore, viDA can target both retailers and 
educators with the same marketing dollar (Tsao, 2004). 
As a result, patients increasingly view dermatologists/cosmetic doctors as having the 
skills and tools to reverse or halt the aging process - and many doctors are more than happy to 
serve as elevated aestheticians. Plenty of dermatologists view selling cosmeceuticals as good 
medical practice. “What we love about dispensing these products is we really know what patients 
are using,” says Patricia Farris, a dermatologist based in New Orleans and clinical assistant 
professor at Tulane University (Tsao, 2004). 
It is expected that among consumers, the popularity of cosmeceuticals will continue to 
rise as long as improving physical appearance remains a top social priority. The medical and 
scientific community’s role in shaping this fast-growing field is expected to be crucial. Recently, 
recognizing the large profits to be extracted from the rapidly growing market, a number of large 
cosmeceutical companies (e.g. L’Oreal) have incorporated medically-trained personnel into their 
workforce. It is apparent that the established companies already recognized these segments as 
being crucial for their products, since it represents a unique dual aptitude, i.e. “client” and 
“purveyor”. Thus partnerships with the medical community will provide viDA with the 
opportunity to extend its market outreach, as well as re-enforce the product brand that stands for 
scientific excellence and quality. 
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3.5.4 Product Diffusion  
Targeting medical professionals first will enable viDA to efficiently diffuse products to 
secondary target segments, as medical professionals recommend viDA products to their patients. 
This will allow diffusion of viDA products to occur with legitimacy and credibility. Medical 
professionals will learn about viDA products through medical conferences, medically-focused 
and results-based seminars and one-on-one meetings.  
Once the evidence of product efficacy is accepted, viDA may ask highly-credible medical 
professionals to voice their opinions (positive feedback) to the public through viDA. Financial 
gains from supplier-induced-demand may also play a role in product diffusion through medical 
professionals, where physicians serve their own interests in prescribing drugs that are financially 
profitable (Dranove, 1988). Innovators and early adopters in the next target segment are the 
people at risk for hairloss which viDA foresees as the group that will create the demand for viDA 
product once they are aware of the efficacy and results. This target segment will be the tipping 
point to bring in the early majority (the baby boomers) as momentum will build with the demand 
from this group.  
 
3.5.5 Competitive Insulation  
viDa’s unique scientific discovery capabilities and patent repertoire gives viDA a 
competitive insulation over its rivals. As an academic start-up biotechnology company, viDA has 
competitive insulation over similar companies, such as Allergan, in that viDA’s technology and 
laboratory infrastructure, coupled with highly trained and qualified personnel, are subsidized by 
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grant money and/or university support in terms of infrastructure, location, and availability of 
personnel such as “start-up-scientists” (i.e. Ph.D. students and post-doctoral research fellows). 
New commercial entrants do not have this level of subsidization and support, and are forced to 
enter the industry based on the merits of their business plans.  The sunk-costs associated with 
starting up serving as a strong barrier to entry for companies not supported by an academic 
institution. viDA’s position as a new entrant is therefore strong and they are in a good position to 
enhance their value proposition to the cosmeceutical industry.  
 
3.5.6  Advantages and Disadvantages 
viDA enjoys a clear advantage of having identified a validated target and initial clinical 
lead. The lead displays specificity to GrB with respect to the overall family of serine proteases. 
In addition, the mechanism of action has recently come to light by virtue of an excellent animal 
model discovered by Dr. Granville’s group (see Fig. 1).  
viDA’s primary disadvantage is that the current lead has an IC50 of around 150 μM 
(micromolar). However using chemical expertise of the scientific advisory team, viDA has 
mapped out a clear protocol for the generation of a targeted library to identify a refined clinical 
lead with greater binding affinity. Proof of concept in an animal model follows a 30-week 
timeline, and the infrastructure and precedence are in place to see the study through to 
completion.  
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3.6 Intellectual Property  
The Intellectual Property that creates the foundation for viDA has been licensed from the 
University of British Columbia, and is made up of three parts:  
1) Methods of treating diseases associated with aging including atherosclerosis, hair 
loss, and loss of skin elasticity/wrinkling where the treatment involves inhibition of 
GrB;  
2) Composition of matter for novel GrB inhibitors; and  
3) Formulation patents for the clinical application of the GrB inhibitors.  
As viDA advances towards clinical trials it is anticipated that additional patents for new 
formulations will also be filed.  
  
3.6.1 Method Patents 
viDA has filed provisional patents relating to the methods of treating disease. The first is 
entitled “Methods of Improving Longevity and Reducing the Cosmetic Effects of Aging” (US 
Provisional serial # 60/780,352, priority date March 9, 2006), which claims methods of reducing 
or reversing the effects of aging on both hair and skin through the inhibition of GrB. This 
provisional application was converted to a full PCT application for global protection of the IP on 
March 9, 2007. Although many formulations are discussed, this application focuses on a topical 
delivery of the clinical lead formulation. Of note, viDA did not claim the application of GrB 
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inhibitors for the treatment of arthrosclerosis. This is because there is prior art that discloses the 
link between arthrosclerosis and GrB activity.  
Table 3 – viDA’s Patent US60/780, 352. 
 viDA Prior Art 
Title:  Methods of Improving Longevity and Reducing 
the Cosmetic Effects of Aging 
Granzyme B inhibitors  
Patent #:  US60/780, 352. WO 03/065987  
Pub/Filed:  2006 2003-08-14/2003-01-31  
Inventor(s):  Cruz RP, McManus, BM, Granville DJ. Merck and Co. INC.  
Significance:  This patent describes methods of reducing or 
reversing the effects of aging on both hair and 
skin through the inhibition of GrB; focuses on a 
topical delivery of the clinical lead formulation 
HIGH: This patent describes the use of a GrB 
inhibitor for the treatment of immunoregulatory 
abnormalities including autoimmune or chronic 
inflammatory diseases. The patent specifically 
mentions treatment of alopecia areata and 
atherosclerosis.  
  
Patent WO 03/065987 describes a specific class of Granzyme B inhibitors, but does not 
have any enabling data. As such, these claims will issue for the composition alone, and not for 
any specific method of use. Alopecia areata is also mentioned, however this is a specific, yet 
infrequent form of hair loss, affecting 1.7% of the population. The market for a product to treat 
hair loss is much greater, 35% of men at 35 years of age and 75% of men at age 80, and is not 
enabled or described in the art.  
The patent literature contained very little relevant prior art. viDA thinks this is due to the 
non-selective nature of serine protease inhibitors. As discussed previously there is a requirement 
for an inhibitor specific to GrB, else dire adverse side effects would occur in the patient. 
However, as evidenced by Dr. Granville’s mouse model, specific inhibition of GrB does not 
interfere with normal development. There are examples of scientific articles that contain 
damaging prior art.  
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Table 4 – Granzyme B prior art  
 Prior Art 
Title:  Extracellular Matrix Remodeling by Human 
Granzyme B via Cleavage of Vitronectin, 
Fibronectin, and Laminin 
Role of cytotoxic T cells in chronic alopecia 
areata. 
Pub/Filed:  J Biol Chem. 2005 Jun 24;280(25):23549-58 J Invest Dermatol. 2000 Jan;114(1):112-6 
Inventor(s):  Buzza MS, Zamurs L, Sun J, Bird CH, Smith 
AI, Trapani JA, Froelich CJ, Nice EC, Bird PI 
Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud 
L, Brousse N, De Prost Y 
Significance:  HIGH: This publications links GrB and cancer 
as it describes an extracellular and perforin-
independent function of granzyme B which may 
contribute to disease progression, specifically 
tissue destruction found in cancer. 
HIGH: This publication links GrB and alopecia 
areata. The authors suggest that the presence of 
GrB may explain the onset of apoptosis in AA 
follicles and that proteinase inhibitors could 
provide a new therapeutic approach. 
 
The two journal articles above again describe a suggested link between GrB and 
atherosclerosis and alopecia areata. It can be surmised that it was Merck’s review of the literature 
for patent WO 03/065987 that led to the method claims within the patent, but the company had 
no enabling data.  
A common theme emerges from the review of the patent and journal literature. In all 
cases of related art, the mechanism of action for extracellular GrB was mediated through 
apoptosis. Two mechanisms were suggested: the first being cell destruction through the 
understood mechanism of perforin enabled cellular entry of GrB, which induces apoptosis; the 
second being GrB cleavage of extracellular matrix proteins like fibronectin that would cause cell 
displacement from its basement membrane, inducing apoptosis through a process called anoikis. 
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In parallel, Dr. Granville’s continuing research pinpointed the actual mechanism of action, which 
was cleavage of elastin by GrB. Elastin is responsible for good tone in the vasculature and the 
skin, as well as the health and composition of the hair follicle. With these new observations 
viDA has filed a second US provisional patent, “Inhibitors of Elastin Cleavage” (serial # 
60/797,352, priority date May 4, 2006). The patent claims the use of GrB inhibitors for the 
treatment of pathologies associated with the degradation of elastin. Having conducted a 
comprehensive search viDA has not located any prior art to this observation. These observations 
were included in the March 9, 2007 PCT application. viDA expects claims to issue for a topical 
medicament consisting of a GrB inhibitor for the preservation of skin elasticity, and the 
prevention of baldness not caused by alopecia areata.  
Table 5 – viDA’s Patent US60/797,352 
 viDA Prior Art 
Title:  Inhibitors of Elastin Cleavage None  
Patent #:  US60/797,352  
Pub/Filed:  2006  
Inventor(s):  Cruz RP, Granville DJ.  
Significance:  The patent claims the use of GrB inhibitors for the 
treatment of pathologies associated with the 
degradation of elastin. 
 
 
3.6.2 Composition of Matter Patent  
viDA is currently pursuing refined clinical leads though construction of an analogue 
library based on the small molecule inhibitor initially identified. Searches for derivatives of the 
original tetrasubstituted furan inhibitor based on the diversity set selected have not returned any 
described compounds. viDA will pursue a composition of matter patent based on the best refined 
leads. This will be novel since the diversity library previously generated will contain molecules 
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that do not perform well in functional assays and some that perform very well. As such, it is 
impossible to predict which compound will be the best candidate, and this aspect will be used to 
teach the novel composition findings from viDA’s refined compound to the patent examiner. US 
provisional patents will be filed on the individual leads, or if possible, a family of leads when the 
studies previously described are completed.  
The Merck patent described above (WO 03/065987) lists a family of GrB inhibitors that 
do not overlap with our compounds of interest. What is more, the GrB inhibitors listed by Merck 
were originally chosen for their ability to bind Granzyme A. As scientific validation continued, it 
was realized that GrB was the more desirable target, and the library focus was shifted mid-
stream. Of particular importance, the Merck compounds will have promiscuity for serine 
proteases in general since they lack the directed strategy of binding the arginine residue specific 
to the GrB active site using carboxylic acid containing leads. This is perhaps why the Merck GrB 
project has seen no further preclinical development as indicated by the PharmaProjects database 
due to the potential for adverse side effects.  
 There is one other patent that describes specific inhibitors of GrB: 
Table 6 – GrB inhibitors prior art 
 Prior Art 
Title:  Induction of immunity using inhibitors of granzymes 
Patent #:  US20030148511A1 
Pub/Filed:  2003-08-07 / 2001-11-14 
Inventor(s):  Ashton-Rickardt Philip G.; Opferman Joseph T. 
Significance:  MEDIUM: The patent describe the use of SPI6 and PI9 or other potential granzyme B 
inhibitors (mimetics, inhibitory antibodies, polypeptide inhibitors, small molecules). The 
SPI6 and PI9 serpins are endogenous inhibitors of granzyme B found in the mouse and 
human, respectively. 
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Patent US20030148511A1 describes a class of peptide based GrB inhibitors found 
endogenously within mammals. Their application is limited solely to cancer. Peptides are not the 
first choice for inhibitors of GrB due to their unfavourable ADME profile.  
  
3.6.3 Freedom to Operate  
viDA’s patent prosecution strategy uses methodology, composition matter, and 
formulation to provide a foundation to insure viDA’s freedom to operate. viDA’s results to date 
and continuing research in Dr. Granville’s laboratory will allow for efficient prosecution of the 
PCT application. This method patent will protect the use of GrB inhibitors to topically treat loss 
of both skin elasticity and hair.  
On the composition of matter front, viDA anticipates the emergence of several, or 
potentially a family, of novel clinical lead compounds. A composition of matter patent on these 
leads will create a powerful portfolio for viDA, and it will reopen the possibility of obtaining 
rights for treatment of cardiovascular disease. This is possible since the methodology for treating 
cardiovascular disease has not been protected by competing patents.  Rather, it has only been 
discussed and prior art exists only in respect to viDA’s method patents.  viDA will investigate 
treatment of cardiovascular disease as a long-term strategy, where pre-clinical work and IP 
generation will be performed in tandem with anti-aging applications.  
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4 THE MARKETING PLAN  
viDA’s lead compound for the anti-aging market will be introduced as a new, exciting 
and effective product in the anti-aging market, based on sound and validated scientific results. 
Maintaining the allure of newness, coupled with a packaged offering is instrumental for success. 
viDA’s market value chain proposition is shown below. 
 
Figure 5 - viDA: Value chain proposition 
 
 
4.1 Overall Marketing Strategy  
viDA’s domestic and international market strategy will initially focus on the medical 
community (for example dermatologists and cosmetic surgeons) championing viDA, with baby 
boomers, as the primary segment of the consumer population targeted.  Business relationships 
are extremely important for viDA’s success, as competing companies in North America that are 
targeting the same segments will challenge viDA. Some initial marketing strategies and 
considerations are: 
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1) Product and Business Development 
a) Plan manufacturing and marketing alliances early 
b) Visit potential larger customers in person 
c) Establish local reputation first then promote internationally  
d) Establish tradeshow schedule and budget and appropriate conferences nationally 
and internationally 
e) Establish travel or entertainment budget for business team 
 
2) Distribution Strategies 
a) Find distributors/retail that will work almost exclusively for viDA 
b) Sign exclusive or semi/exclusive contracts with distributors. (Well-educated 
distributors know how to get approvals (one reason for exclusivity) 
c) Select distributors that have an in-depth market understanding (e.g. regional 
expertise, professional associations [doctors], consumer segments)  
d) Consider and organize shipping and delivery (UPS, FEDEX, DHL). Avoid 
services with limited tracking and insurance mechanisms for lost merchandise 
e) Establish paying mechanisms (wire transfer or credit, establish a credit period 
before considering credit for a customer 
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3) Promotional and Marketing 
a) Decide on direct (e.g. catalogs, TV, internet, multilevel marketing) and indirect 
(drug stores, spas, department stores, doctor’s offices) sales strategy 
b) Consider labeling and language issues (e.g. in Canada Quebec slightly different as 
rest of Canada, Canadian-English versus American-English, and US States may 
have separate requirements. 
c) Send samples, marketing literature and documents (consider expenses as this can 
add up especially with shipping) 
d) Decide which products to sell first and in which market 
 
4) Brand and Patent Strategies 
a) Consider regulatory issues in a timely manner, as cosmeceuticals must be 
registered 
b) Establish strong mechanisms for copying and patent protection (for Canada and 
the US). Note, registration process can be lengthy. Professional organizations 
(e.g. US department of Commerce and the Canadian Chamber of Commerce) can 
help with what is needed.  
c) Establish a good relationship with US department of Commerce and Canadian 
Chamber of Commerce 
d) Commerce department will be instrumental in screening potential clients 
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e) Commerce departments have market research available 
 
Cosmeceutical company Prevage succeeded through a co-marketing agreement between 
Allergan and Elizabeth Arden with two main products, a physician strength PrevageMD that 
contains 1% idebenone (the patented ingredient) and an E. Arden cosmetic over the counter 
Prevage containing 0.5% of idebenone. The result was growth for the first three months that was 
10% over the corresponding period of the preceding year and with the dermatology business also 
benefiting from sales and launch quantities of Prevage. viDA will establish a similar marketing 
value proposition exploiting its core strengths of research and business development and 
partnerships in the areas of manufacturing and sales/distribution. 
Based on viDA’s internal resources, skills and capabilities, viDA will focus on research 
and development and will require a partner to execute marketing and distribution of its products. 
viDA can potentially seek a co-marketing distribution with the following companies:  L’Oreal, 
Sephora and Lifebrands.   
L’Oreal represents a large, established, reputable company that is international, 
vertically-integrated, have high-end products (eg. Lancome, Kiehl’s, Biotherme, Shu Uemura, 
Helena Rubenstein), mid-range products (eg. L’Oreal professional, Redken, Vichyand, 
Skinceuticals) and low-end products (eg. Maybelline and Garnier).  If viDA partners with 
L’Oreal, they will have access to global distribution and marketing channels and may adopt 
some marketing and distribution strategies.   
Sephora is the leading retail beauty chain in Europe and recently present in the US.  
Sephora is the child company of Moet Hennessey Louis Vuitton.  If viDA partners with Sephora, 
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high-end products will be the focus.  Like L’Oreal, Sephora’s global presence in marketing and 
distribution is well-established.  Given viDA’s projected position within the competitive 
landscape as a high-quality product, partnering with Sephora would be viDA’s optimal alliance. 
Lifebrands, conversely, represents higher accessibility to a larger consumer market who 
readily adopt new brands and are price-sensitive.  An alliance with Lifebrands will enable viDA 
to enjoy mass market appeal and access to profits from large numbers of sales as opposed to 
partnership with Sephora where viDA will enjoy higher profitability per product sales that is 
inherent in the brand exclusivity. 
Figure 6 - viDA’s marketing proposition 
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4.2 Pricing  
The pricing for viDA products will evolve as efficacy is proven and with reference to 
high-end competitors pricing and perceived customer value in the selected market segments. 
viDA is targeting the price category of Prevage (Allergan/Elizabeth Arden), one of the most 
successful and effective products in the market for the last couple of years. The price will need to 
be either similar or competitively lower in the range of $299 to $399. Together, the price and the 
improved efficacy viDA intends to achieve with its lead compound will place viDA in a 
competitive position in the industry (see positioning map below). 
 
Figure 7 – viDA’s Positioning Map 
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4.3 Field Sales Tactics  
viDA’s marketing and distribution partner(s) will establish relationships with medical 
professionals by recruiting experienced pharmaceutical sales representatives to target cosmetic 
surgeons, dermatologists, and medical professionals specializing in anti-aging. Ongoing site 
visits to medical centers and doctors’ offices will be essential to driving awareness and adoption 
by the medical professional target segment. viDA’s marketing and distribution partner(s) will 
also target dermatology and cosmetic surgery conferences as prime venues for advertising, 
sponsorship, product sampling and education. By primarily focusing marketing campaigns on 
medical conferences, viDA will maximize marketing value and sales area coverage because of 
the fact that physicians practicing globally are concentrated in one location. 
As viDA’s product gains adoption by medical professionals and the company starts to 
enjoy sales revenues, viDA’s marketing and distribution partner(s) can increase marketing efforts 
to include secondary target markets. This may involve pursuing relationships with national retail 
chains that will set up highly visible retail Point-of-Sale displays focused on producing 
impacting, memorable and persuasive product messaging. Because viDA’s marketing and 
distribution partner(s) will continue to deploy sales agents to physician’s offices, consumers will 
be drawn to viDA’s products through a pull and push mechanism of sales. 
 
4.4 Advertising and Sales Promotions  
Advertising at medical conferences and within medical journals will be key to viDA’s 
publicity campaign to medical professionals. viDA’s marketing and distribution partner(s) may 
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also use product sampling as a primary method of encouraging adoption by the physicians 
practicing dermatology, cosmetic surgery or anti-aging. Similarly, viDA’s marketing and 
distribution partner(s) will consider product sampling to secondary target markets during focused 
marketing campaigns.  
As companies within the biotech and pharmaceutical industries increasingly target 
consumers directly to improve the visibility of their products and brands, an important option for 
viDA to consider is direct-to-consumer-advertising (DTCA). Although DTCA is only legal in the 
USA and New Zealand amongst all the industrialized nations, viDA may consider establishing 
an American arm to facilitate ongoing consumer adoption. Consumers exposed to DTCA are 
twice as likely as those not exposed to DTCA to request specific advertised drugs, as well as 
prescriptions for those drugs (Mintzes et al., 2003). An excellent example of this can be seen in 
the case of hGH, where Genentech was actually awarded for their marketing efforts in promoting 
hGH products targeted primarily at a consumer audience in 2007 (Media, 2007). Genentech’s 
campaign aimed to enroll 25% of identified hGH patients in the "Stepping Stones" support 
program. Three months post-launch, greater than 40% of physicians anticipated increasing 
prescriptions because of the program. Therefore, viDA’s marketing and distribution partner(s) 
will consider DTCA for long-term advertising and sales promotion campaigns, and accordingly 
comply with the appropriate regulatory, legal and logistical challenges to exercising this option. 
 
5 PRODUCT DEVELOPMENT STRATEGY AND REGULATORY GUIDELINES  
viDA’s main product development goal will be to generate, validate and implement new 
anti-aging product concepts and product lines that will ensure the planned growth of the 
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company. viDA’s primary objective is to further develop basic research on granzyme B 
inhibitors for both the antiaging industry as well as the cardiovascular market. Therefore, viDA 
can outsource standard R&D activities to a CRO, such as large scale target identification and 
synthesis, and partner with companies that are experienced in marketing and distribution.  
viDA will capitalize on a line of products that will create strong, differentiating 
messaging in the anti-aging cosmeceutical industry.  viDA will offer a mix of product price-
points within the various product categories and manage the timing of product introduction by 
bringing some products to market quickly, followed by supplementary and added-value product 
lines. The figure below represents viDA’s strategic product development for the first years. 
While viDA will focus predominantly on developing products for the anti-aging market, 
pre-clinical and IP development for products destined for the cardiovascular market will proceed 
in tandem. By working on both indications during early research and development stages, viDA 
will leverage existing research and financing using animal models, where additional investment 
to develop data for a second indication will be minimal. 
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Figure 8 – viDA’s Strategic Development of Product Lines 
 
After successfully introducing its first line of products as seen above, viDA may use 
revenues and/or additional financing to either diversify, by expanding into the segment of hair 
loss, or continue to build brand recognition with face care. 
In order to understand the regulatory challenges that viDA may face, the definition of 
“cosmeceuticals” must be understood. Cosmeceuticals or cosmetic pharmaceuticals are cosmetic 
products that contain biologically active ingredients and claim to have medicinal or drug-like 
benefits. Raymond Reed, founding member of the US Society of Cosmetic Chemists, coined the 
term in 1961 (Wang, 2008).  
While the Food, Drug, and Cosmetic Act (U. D. o. H. a. H. Services, 2004) does not 
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recognize the term "cosmeceutical," the cosmetic industry uses this word to refer to cosmetic 
products that have medicinal or drug-like benefits. The Food, Drug, and Cosmetic Act defines 
drugs as those products that cure, treat, mitigate or prevent disease or that affect the structure or 
function of the human body. While drugs are subject to a review and approval process by FDA, 
cosmetics are not approved by FDA prior to sale. If a product has drug properties, it must be 
approved as a drug (U. H. a. H. Services, 2002).  
viDA will be aware of the regulatory requirements and will avoid claims stated on the 
product labeling, in advertising, on the Internet, or in other promotional materials that may cause 
its products to be considered a drug. viDA will educate the consumer so that the consumer’s 
perception is accurate and thus, establish brand and product reputation. 
Moreover, since cosmeceuticals are products that affect structure and function of skin, 
which are like drugs but are marketed with claims based on appearance of skin, i.e. “reduce the 
appearance of wrinkles”, clients will expect that viDA will play an important role as a consultant 
and evaluator of the procedures for both its non-prescription and prescription for safety and 
efficacy. The experimental preclinical and clinical trials do not need to be as stringent as FDA 
would recommend for a New Drug Application (NDA), however some minimal standards will 
need to be established. 
As a paradigm, viDA may use Allergan’s design for small clinical trials that established 
efficacy and effectiveness of its substance Idebenone (ingredient of Prevage and Prevage MD). 
Effectiveness of Idebenone was established on three clinical studies with small number of 
subjects (one with n=29 and two with n=18, using different concentrations) all analyzed by 
dermatologists. By using the simpler clinical trial model as applies for cosmeceuticals, viDA will 
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be able to establish the scientific foundation of Granzyme B. This will add value to the company 
as viDA will enter the market and launch a credible brand name that would be synonymous to 
both, highly marketable and scientifically validated quality products.  
 
5.1 Develop a refined clinical lead ($580k) 
The search to identify a promising clinical lead for GrB inhibition was successful, and 
has confirmed the synthetic protocol for its creation. The incorporation of parallel/combinatorial 
methodologies is ideal for the refinement of viDA’s clinical lead compound. The lead is a 
tetrasubstituted furan that possesses no chiral centers and is highly symmetrical. The dihydroxy 
furan can then serve as a “core” structure in which different groups (diversity reagents) can be 
attached via an ether linkage to the hydroxyl groups at positions 3 and 4 using parallel 
chemistries.  
The chemistry work will be carried out by a specialized chemistry CRO. This is an 
emerging and competitive market with centers in the US, Canada, India and Eastern Europe. 
Under confidentiality, a group will be chosen based first on a track record for milestone based 
results, and second on cost.  
The ability of the individual analogues derived from the initial clinical lead to inhibit GrB 
activity can be easily quantified using commercially available kits such as the Innozyme GrB 
Fluorometric Activity Assay Kit from CalbioChem. Available in a 96 well format, a known 
amount of GrB and analogue are added to a well which contains a modified pro-urokinase that 
serves as a substrate. When cleaved by GrB, the urokinase is activated and is able to cleave the 
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fluorogenic substrate (Glutaryl Gly-Arg AMC), releasing AMC. AMC is measured 
fluorometrically. In this manner the activity of the analogues can be rapidly determined at low 
cost.  
From the in vitro results, the experimental approach to study the three best leads in an in 
vivo animal model is relatively straightforward. As part of the stability assays, the pK, or plasma 
half-life of the potential leads will be determined through mass spectroscopy. Briefly, wild type 
control mice will be injected with three doses of the potential lead; low, medium and high doses 
where the medium dose is the anticipated therapeutic level as determined from the in vitro GrB 
functional inhibition assay and the low and high doses are half and double respectively. Blood 
draws will occur every 30 minutes over a four hour period using eight mice per dosage such that 
only one draw per mouse will occur. The plasma will be separated, immediately frozen and 
shipped to the University of Victoria Proteomics Facility to determine the concentration of the 
lead in plasma over time. From this analysis a pK will be calculated, which will determine the 
therapeutic dose for the in vivo animal studies.   
 
5.2 Establish efficacy in an animal model for GrB mediated pathogenesis ($1.5 million) 
In vivo assessment of the leads will start with eight-week old GrB/ApoE-double knock 
out mice, alongside the appropriate age-matched single knockout and wild type controls. For 
each of the three lead compounds to be studied, the experiments will use four GrB/ApoE-double 
knock out mice, four GrB-knock out mice, four ApoE knockout mice and four controls, for a 
total of 16 mice per lead. An additional set of 16 untreated mice will be used as the negative 
control. All experimental animals will be fed a high-fat Western diet for the 30 week course of 
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the experiment. Beginning at week 20 the experimental mice will receive twice daily injections 
of one of the lead compounds for 10 weeks, at which time the animals will be sacrificed and 
atherosclerotic plaques, skin lesions and hair loss will be quantified. The effectiveness of the 
GrB inhibitors will be judged on their ability to limit plaque formation, skin lesions and hair loss. 
Gross pathology will be performed on the mice to search for signs of adverse side effects.  
An initial seed round investment of $1.5 Million will result in a refined clinical lead that 
has been validated in an animal model, with an established mechanism of action. This is an 
excellent staging ground for a Series A financing to permit the completion of GMP and GLP 
preclinical trials and entry into clinical development.  
 
5.3 Carry out GMP, GLP preclinical development and IND Application: topical 
($1,722k) and cardiovascular ($2,472k) 
Following a Series A financing of viDA, the company will complete the required Good 
Manufacturing Process (GMP), and subsequent Good Laboratory Process (GLP), testing required 
to complete the preclinical phase of development and file the Investigational New Drug (IND) 
application in order to proceed to clinical trials. As part of viDA’s growth as a company, a key 
hire at this point will be an individual with a track record in preclinical development and early 
clinical development. This individual will coordinate the continued refinement of the clinical 
lead that includes formulation development, stability refinement and ultimately manufacture of 
the drug formulation viDA will carry forward to the clinic. This work will be performed by an 
outside CRO. Following manufacture of the individual formulations for both topical and 
cardiovascular applications, extensive absorption, distribution, metabolism, and excretion 
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(ADME) studies will be carried out, followed by toxicology (Tox). While the ADME-Tox 
requirements are well defined and straightforward, the associated costs are large; in the order of 
$750k per formulation. With manufacture and ADME-Tox profiling in hand, viDA will first 
request a briefing meeting with the FDA, and then prepare and file an IND.  
  
5.4 Carry out clinical development: topical ($350k)  
FDA review of the application requires approximately 30 days. During the intervening 
time viDA will be in the final stages of preparing for the initiation of a Phase 1 trial for the 
topical formulation. The clinical trial planning will have begun, with most of the planning 
revolving on enrolling interested physicians across North America who would like to participate 
in the trial. These efforts will be facilitated by recruitment of key clinical “thought leader” in the 
field onto the viDA Scientific Advisory Board (SAB). Our SAB members will spread viDA’s 
scientific and clinical development through top-tier medical conferences. The resulting interest 
will fuel site recruitment in advance of notice of approval for the IND by the FDA.  
With the resulting data for the preclinical development nearly complete, protocol design 
for the Phase 1 trial will begin at viDA using our SAB and an outside group of expert 
consultants.  
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6 OVERALL SCHEDULE  
viDA’s operational strategy seeks to aggressively achieve measurable milestones.  
Table 7 – viDA’s yearly milestones 
YEAR  MILESTONE  
Year 1  Develop a refined clinical lead ($580k). 
 Establish efficacy in an animal model for GrB mediated pathogenesis ($1.5mil) 
Year 2 Carry out GMP, GLP preclinical development and IND Application:  
topical ($1,722k) and cardiovascular ($2,472k) 
Year 3-5 Carry out clinical development: topical ($350k) 
 
 
7 FINANCIAL NEEDS, EQUITY STRUCTURE AND RETURN ON INVESTMENT  
7.1 Start-up  
viDA’s start-up time is estimated to occur over eight months and will require $3 million 
Canadian dollars.  These funds will be used to establish adequate laboratory facilities and create 
the complimentary infrastructure necessary to begin operations.  These requirements include but 
are not limited to: laboratory equipment, property, legal and administration, salaries and funds to 
support selected contract research organizations.  Upon commencing operations, viDA will 
require an additional $6,000,000 to ensure adequate cash flow over the following years of 
operations. 
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7.2 Proposed Equity Structure  
Table 8 - Capital Structure 
Shareholders Pre-Investment Seed Round (2008) 
$1,500,000 
Series A (2009) 
$6,000,000 
       
Founders Shares Percent Shares Percent Shares Percent 
Alistair Duncan 900,000 30 900,000 15 900,000 6.8 
Harry C. Ledebur 600,000 20 600,000 10 600,000 4.5 
David Granville 600,000 20 600,000 10 600,000 4.5 
Management (TBD) 300,000 10 300,000 5 300,000 2.25 
Friends and Family 240,000 8 240,000 4 240,000 1.8 
Rani Cruz 180,000 6 180,000 3 180,000 1.35 
UBC 180,000 6 180,000 3 180,000 1.35 
       
Total 3,000,000 100 3,000,000 50 3,000,000 22.7 
       
Investors       
Seed   3,000,000 50 3,000,000 22.7 
Series A     7,200,000 54.6 
       
       
Total # Shares 3,000,000 100 6,000,000 100 13,200,000 100 
       
Value per Share $0.50  $0.50  $0.84  
Company Valuation 
(post-money) 
1,500,000 
(pre-
money) 
 3,000,000  11,048,000  
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7.3 ROI: Comparable Companies, Market Caps and P/E ratios  
1) Allergan, Inc.: A multi-specialty healthcare company, discovers, develops, and 
commercializes specialty pharmaceutical, medical device, and over-the-counter products 
for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast 
aesthetics, obesity intervention, urological, and other specialty markets worldwide, with a 
market cap of $16.26 B on 305 million common shares.  While the company is currently 
enjoying revenue growth (22%) it is posting positive EBITDA ($1.11 B), with the 
forward P/E ratio is projected to be 17.36 for the year ending 31/12/09.  
2) Medicis Pharmaceutical Corporation: Focusing primarily on the treatment of 
dermatological and podiatric conditions and aesthetics medicine, with a market cap of 
$1.17 billion on 56.44 million shares outstanding.  The company reports year-over-year 
revenue growth of 38.1% on positive earnings ($150.94 million); with, the forward P/E 
ration of is projected to be approximately 11.3 for the year ending 31/12/09. 
 
While both of these companies have established operations within the anti-aging market, 
their growth and operation are believed to reflect viDA’s potential within the industry. 
Therefore, referencing the projected P/E ratios for these two companies, viDA conservatively 
estimates a multiplier of 10 to apply to viDA’s EBITDA to estimate the terminal value of the 
company in future years.  
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7.4 ROI: Exit Strategy  
viDA can envision two exit strategies: - an Initial Public Offering (IPO) on the public 
markets or sale to larger pharmaceutical or cosmetic companies.  If viDA considers an 
acquisition, the main priority would be to ensure maximization of shareholder value.  In light of 
the average 40% discount expected in most acquisitions, viDA will compare this option carefully 
with an initial public offering.   
As viDA creates value in developing anti-aging and cardiovascular product pipelines, the 
company will seek acquisition by major industry players, such as large Pharma and established 
cosmetic companies. Large pharmaceutical companies like Merck and Pfizer are 
actively researching new prescription compounds for cosmetic purposes. In 2007, Pfizer 
acquired Anaderm, based in Ann Arbor, Michigan. Anaderm is working on drugs to tackle five 
common cosmetic concerns: age spots, oily skin, hair loss, excess hair and sun 
damage. Currently, Pfizer's open interest in cosmeceuticals seems to be an exception, rather than 
the rule. Merck, which markets Propecia, regards its product as an outlier, and it is continuing to 
concentrate on major diseases such as diabetes. Moreover, sales for Propecia have been 
relatively modest for Merck, at $98 million worldwide, and rising only 4% in the US market.  
Large, well-established cosmetic companies that can afford expensive research and 
clinical trials required to bring a new drug onto the prescription market represent a second 
potential acquirer. Precedent for this concept can be seen with the creation of Galderma. 
Cosmetics giant L'Oréal, for example, teamed up with the food and drinks conglomerate Nestlé 
in 1981 to create a dermatology-research company called Galderma, headquartered in Lausanne, 
Switzerland. The company is seeking new drugs for aging skin and/or balding.  
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Thus, viDA’s exit options are potentially vast, as exit through acquisition includes not 
only traditional pharmaceutical companies, but large cosmetics organizations as well. 
 
8 CRITICAL RISKS, PROBLEMS AND ASSUMPTIONS  
Several risks hve been identified and ordered in priority: 
• Adverse events and target ineffectiveness may serve as viDA’s primary risks as a drug 
development biotechnology company. viDA may mitigate this risk by ensuring adequate 
financing exists prior to the exposure of any negative results, which will serve to support 
additional rounds of target development and testing. viDA may also consider licensing 
the rights to granzyme therapy development for either anti-aging or cardiovascular 
therapy to enable complete focus on one indication. 
• The inherent risk in biotechnology ventures often leads to high percentage equity 
financing for these ventures. Therefore, board management is essential to maintaining the 
correct focus and leadership required for growing biotechnology companies. viDA may 
mitigate any risk in this area by actively managing board members to reflect the needs of 
the venture during its various stages of growth. 
• The importance of Intellectual Property in biotechnology requires extreme due diligence 
in protecting property rights. viDA may mitigate any risks in IP challenges by seeking 
out and establishing excellent relationships with IP lawyers specializing in licensing, 
contract and corporate law in biotechnology. 
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• Completion of viDA’s first product and sales are anticipated to occur according to 
traditional drug development scheduling, however unforeseeable circumstances may 
delay the product development and sales schedule. Rigorous project and product 
management protocols will be developed implemented to help mitigate this risk. 
• Inadequate marketing against established competitors leads to dismal sales/revenues; 
viDA will ensure that the selected marketing and distribution partner(s) will focus on 
creating an effective marketing campaign. Establishing viDA as a brand may serve to 
mitigate this risk.  
• Superior technologies will minimize the impact viDA’s products.  viDA will monitor 
competing technologies closely and increase research, development or marketing efforts 
appropriately. 
 
9 CONCLUDING STATEMENT 
viDA Therapeutics Inc. was created in 2008, when its founders recognized that the 
booming demand for quality cosmeceutical products is a unique opportunity for their scientific 
discoveries. viDA is based on ground-breaking research that has the potential to revolutionize the 
cosmeceutical industry.  The intellectual property owned by viDA, the team assembled and the 
support from the local academic and business community will facilitate its successes. 
Furthermore, viDA is poised to be the first mover in the area of elastin-inhibiting cosmeceutical 
therapy for anti-wrinkling and hair regeneration. 
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viDA is seeking $1.5 million for the seed round and an additional $6 million in series A 
financing to develop the products in the large anti-aging market. With revenues of $56 billion a 
year in 2006, the anti-aging market is targeted to reach $79 billion by 2009 market, with a 
potential of reaching $111 billion by 2012.  
The company’s key assets are primarily its patents, its tacit scientific knowledge and its 
dedication to represent BC’s independent provider of aesthetic medicine products and services to 
doctors. viDA is led by an experienced professional group comprised of scientists, physicians, 
business consultants and technical experts, that strive to be a long-term, trusted partner for their 
local and international partners and clients. 
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10 APPENDIX I – MARKETING ANALYSIS  
10.1 Target Market Segmentation Analysis 
The four top market segments for viDA include medical professionals, people at risk for 
hair loss, baby boomers, and beauty conscious women. The following table lists details of each 
segment.  
Medical Professionals 
Canadian dermatologists = 580 
cosmetic surgeons = 600  
Canadian cosmetic surgery clinics = 33 
Dermatology clinics = 24  
Aesthetic Plastic Surgery = 2400  
American Academy of Dermatology = 16,000  
Total = 31,137  
  
People at Risk for Hair Loss 
40-50% of men and women experience hair loss by the age of 50 
people aged 20-65 in N.A. = 202,943,269  
= 202,943,269 x 50%  
Total = 101,471,634.5  
  
Baby Boomers  
North American pop age 44-64 = 87,330,104  
Total = 87,330,104  
  
Beauty Conscious  
Females aged 30-49 = 47,194,569 
81% full time employed with average income @ $36k/yr)  
= 47,194,569 x 81% full time employed with average income @ $36k/yr  
Total = 3,822,761.79  
 
Data based from: (Bureau, 2008a, 2008b; Buyer, 2008; Canada, 2008; Cosmeticdesign.com, 
2004; Dermatology, 2008; Health, 2008; Surgeons, 2008; Surgery, 2008) 
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11 APPENDIX II – FINANCIAL STATEMENT  
11.1 Income Statement  
Pro Forma Income Statement 
 2008 2009 2010 2011 
     
R&D (Topical) 202,500 277,500 1,602,500 1,670,000 
R&D (Cardio) 202,500 377,500 2,192,500 500,000 
General and Administrative 200,000 250,000 500,000 700,000 
Patents 100,000 150,000 250,000 250,000 
Total Operating Expenses 705,000 1,055,000 4,545,000 3,120,000 
     
Interest Income 30,000 12,500 160,000 60,000 
SR&ED Credits 0 162,000 262,000 1,518,000 
Grants 150,000 250,000 0 0 
Financing 1,000,000 6,000,000 0 0 
Total Non-Operating Income 1,180,000 6,424,500 422,000 1,578,000 
     
Net Income 475,000 5,369,500 -4,123,000 -1,542,000 
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11.2 Annual Balance Sheet  
Pro Forma Balance Sheet (December 31) 
 2008 2009 2010 2011 
     
Assets     
Cash 475,000 4,844,500 1,721,500 179,500 
Short Term Investments 0 1,000,000 0 0 
Intangible Assets (IP, Management) 1,500,000 5,000,000 8,000,000 20,000,000 
     
Total Assets 1,975,000 10,844,500 9,721,500 20,179,500 
     
Liabilities     
Accounts Payable 50,000 75,000 100,000 150,000 
     
Shareholders’ Equity     
Common Stock 1,925,000 10,769,500 9,621,500 20,029,500 
     
Total Liabilities 1,975,000 10,844,500 9,721,500 20,179,500 
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11.3 Financial Assumptions  
• To account for inflation, most operating (e.g. Property lease, legal etc.) and R&D costs 
were increased at 2% /year. 
• Property lease cost is based on $38/sq ft/yr (industry average). 
• Insurance estimate are based on $30,000 base insurance for property, workers comp etc. 
• Increasing intangible assets are assumed to represent increased value of existing IP, as 
well as the acquisition and development of additional patents and intangible assets. 
